An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hyogo, Japan, 663-8501
- Hyogo College of Medicine Hospital
-
Miyagi-Ken, Japan, 980-8574
- Tohoku University Hospital
-
Osaka, Japan, 565-0871
- Osaka University Hospital
-
Yokohama, Japan, 240-8555
- Yokohama Municipal Citizen's Hospital
-
-
Hiroshima-ken
-
Hiroshima-shi, Hiroshima-ken, Japan, 734-8551
- Hiroshima University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants who meet all of the following criteria will be enrolled in this study:
- Ability to voluntarily provide written, signed, and informed consent to participate in the study.
- Completion of the SHP633-306 study or participation in TED-C14-004 (NCT02340819) Stage 3 or Stage 4.
- Females of childbearing potential must agree to comply with the contraceptive requirements of the protocol.
- An understanding, ability, and willingness to fully comply with study procedures and restrictions.
Exclusion Criteria:
There are no exclusion criteria for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Teduglutide 0.05 mg
Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
|
Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Teduglutide will be administered using needle.
Needle is approved for use in Japan by PMDA.
Vial adapter for device is approved for use in Japan by PMDA.
Teduglutide will be administered using syringe.
Syringe is approved for use in Japan by PMDA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)*7.
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Change From Baseline in Weekly PS Volume
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)*7.
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Percent Change From Baseline in Weekly PS Volume
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)*7.
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)
Time Frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
|
|
Change From Baseline in Days Per Week of PS
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Change From Baseline in Plasma Citrulline Levels
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Plasma citrulline was measured as an assessment of enterocyte mass.
Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time Frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
|
|
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS
Time Frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
|
|
Change From Baseline in 48-Hour Urine Output
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Clinically Significant Change From Baseline in BMI
Time Frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
Baseline data refer to the baseline of core studies (SHP633-306 [NCT03663582] or TED-C14-004 [NCT02340819]), however the time frame represents the duration for which participants were assessed in current study.
The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
|
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
|
|
Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results
Time Frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHP633-307
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.